Genesis Cancer Care-CHURCHILL Hospital Headington
Welcome,         Profile    Billing    Logout  
 2 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Protheroe, Andrew
RAMPART, NCT03288532 / 2017-002329-39: Renal Adjuvant MultiPle Arm Randomised Trial

Hourglass Oct 2023 - Dec 2023 : From RAMPART trial with or without in combination with tremelimumab
Recruiting
3
1750
Europe
Durvalumab, Tremelimumab
University College, London, AstraZeneca, Kidney Cancer UK, Cancer Research UK
Renal Cell Carcinoma
07/24
12/34
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting
3
804
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26

Download Options